HTB
-
Featured
UK guide to PrEP now online: major update (2024)
1 March 2024. Related: Editorial, Special reports.
-
Featured
HTB 2024: weekly news posted online
3 January 2024. Related: Editorial.
-
Featured
HTB December 2023/January 2024
1 December 2023. Related: Editorial.
-
Featured
HTB October/November 2023
1 October 2023. Related: Editorial.
-
Featured
HTB September 2023
1 September 2023. Related: Editorial.
-
Featured
HTB May/June 2023: HIV and implementation science
1 June 2023. Related: Editorial.
-
Featured
HTB April 2023 (6 April 2023)
6 April 2023. Related: Editorial.
-
Featured
HTB March 2023 (10 March 2023)
10 March 2023. Related: Editorial.
-
Featured
HTB January/February 2023 (1 February 2023)
1 February 2023. Related: Editorial.
-
Featured
In memory: Timothy Ray Brown – the Berlin patient, the first person to be cured of HIV
14 October 2020. Related: In memory.
-
ART in early infection stops further viral evolution
21 April 2024. Related: Antiretrovirals, Virology.
-
Australia Consensus Statement on doxy-PEP proposes limited use in gay and bisexual men
10 April 2024. Related: Guidelines, Coinfections and complications, Other news.
-
CROI 2024 now online and open access
10 April 2024. Related: Conference reports, CROI 2024 Denver.
-
Uganda Court rejects appeal against the LGBTQ+ hate law
5 April 2024. Related: Special reports, Treatment access.
-
BHIVA best of CROI webinars now online
4 April 2024. Related: Conference reports, CROI 2024 Denver.
-
Future meetings and webinars 2024
1 April 2024. Related: Future meetings.
-
CROI 2024: Opening lecture calls for scientists to speak up for LGBTQ+ rights in Uganda
24 March 2024. Related: Conference reports, Treatment access, Women's health, Pregnancy, Vaccines and microbicides, CROI 2024 Denver.
-
Roche to discontinue enfuvirtide (T-20, Fuzeon)
24 March 2024. Related: Antiretrovirals.
-
CROI 2024: Pipeline ART – new drugs and formulations
19 March 2024. Related: Conference reports, Antiretrovirals, CROI 2024 Denver.
-
CROI 2024: Studies using tecovirimat to treat mpox
16 March 2024. Related: Conference reports, mpox (monkeypox), CROI 2024 Denver.
-
CROI 2024: Promising results from first study of long-acting treatment in Africa
10 March 2024. Related: Conference reports, Antiretrovirals, Treatment access, CROI 2024 Denver.
-
CROI 2024: HIV studies with semaglutide: significant benefits but limited access for treatment and research
10 March 2024. Related: Conference reports, Lipodystrophy and metabolic complications, CROI 2024 Denver.
-
CROI 2024: studies to watch for at this upcoming conference
1 March 2024. Related: Conference reports, CROI 2024 Denver.
-
US guidelines recommend earlier use of statins in people living with HIV
1 March 2024. Related: Guidelines, Lipodystrophy and metabolic complications.
-
Modelling study challenges links between gender and PrEP: event-based dosing and easier daily dosing should work for all
12 February 2024. Related: Special reports, HIV prevention and transmission.
-
UK HIV Positive Voices survey: many people doing well but life is still difficult for others; growing belief in U=U
9 February 2024. Related: Special reports, Ageing and life expectancy, Treatment advocacy, Research studies, Other news.
-
Mpox updates: recent publications (2024)
2 February 2024. Related: mpox (monkeypox).
-
Remarkable impact of DNDi over 20 years
24 January 2024. Related: Other news, On the web.
-
BHIVA recommendations on measles in the UK
23 January 2024. Related: Guidelines, Coinfections and complications, BHIVA news.
-
Liverpool Drug Interactions: January update
17 January 2024. Related: PK and drug interactions.
-
Five cases of viral failure on CAB-LA and RPV-LA injections
15 January 2024. Related: Antiretrovirals, Drug resistance.
-
Clinical efficacy of tecovirimat for treatment of mpox in people living with HIV
10 January 2024. Related: mpox (monkeypox).
-
BHIVA update guidance on shingles vaccine
9 January 2024. Related: Guidelines, Coinfections and complications, Basic science and immunology, Vaccines and microbicides, BHIVA news.
-
PrEP douche achieves more protective drug levels than 2:1:1 oral dosing
9 January 2024. Related: HIV prevention and transmission.
-
Uganda hate law blocks HIV research: join 300 leading researchers in sign-on protest
4 January 2024. Related: Special reports, Treatment access, Treatment advocacy, Research studies.
-
Uganda update: LGBT hate law challenged in the courts
3 January 2024. Related: Special reports, Treatment advocacy.
-
FDA warns Amazon over supplements containing Viagra: hundreds of cases reported over ten years
2 January 2024. Related: PK and drug interactions, Other news.
-
i-Base 2024 appeal: support for LGBTQI+ refugees in Kakuma
1 December 2023. Related: Editorial.
-
14th International Workshop on HIV and Ageing
1 December 2023. Related: Conference reports, Ageing and life expectancy, Conference index, HIV and Ageing 2023.
-
Sarcopenia and mitochondrial dysfunction in people living with HIV: the impact of ageing
1 December 2023. Related: Conference reports, Ageing and life expectancy, HIV and Ageing 2023.
-
Measuring sarcopenia in people living with HIV
1 December 2023. Related: Conference reports, Ageing and life expectancy, HIV and Ageing 2023.
-
Latest figures published on HIV in the UK: 2023 report
1 December 2023. Related: Special reports, HIV prevention and transmission.
-
19th EACS (EACS 2023)
1 December 2023. Related: Conference reports, Conference index, EACS 19 Warsaw 2023.
-
EACS 2023: HIV cure-related research
1 December 2023. Related: Conference reports, Cure-related research, EACS 19 Warsaw 2023.
-
EACS 2023: European guidelines fully revised (October 2023)
1 December 2023. Related: Conference reports, Guidelines, EACS 19 Warsaw 2023.
-
EACS 2023: Prevalence of doravirine drug resistance in large cohort in British Columbia
1 December 2023. Related: Conference reports, Research studies, EACS 19 Warsaw 2023.
-
EACS 2023: Switching to daily fixed-dose doravirine/islatravir: 96-week results
1 December 2023. Related: Conference reports, Antiretrovirals, EACS 19 Warsaw 2023.
-
First-line ART drops below US $45 a year for low-income countries
1 December 2023. Related: Antiretrovirals, Treatment access.
-
EACS 2023: TDF/FTC dual-nuke ART: not supported by ALTAR study
1 December 2023. Related: Conference reports, Treatment strategies, EACS 19 Warsaw 2023.
-
EACS 2023: EATG video campaign against HIV stigma
1 December 2023. Related: Conference reports, Other news, On the web, EACS 19 Warsaw 2023.
-
Potential for monthly injectable: nanoformulated tenofovir/3TC/dolutegravir
1 December 2023. Related: Antiretrovirals.
-
Dolutegravir monotherapy still not recommended: 4-year follow up in early-treated durably suppressed participants
1 December 2023. Related: Treatment strategies.
-
CD4:CD8 ratio recovery reduces with higher age when starting ART
1 December 2023. Related: Treatment strategies, Basic science and immunology.
-
CHAI 2023 market report: decline in HIV funding threatens 20 years of progress
1 December 2023. Related: Treatment access.
-
Modest increase in rate of cardiovascular disease progression during perimenopause for women living with HIV
1 December 2023. Related: Women's health.
-
Review of US PEPFAR programme highlights continued higher infant mortality
1 December 2023. Related: Paediatric care, Other news.
-
Oral tenofovir/FTC increases clearance of bNAb VRC01: implications for future research
1 December 2023. Related: PK and drug interactions, HIV prevention and transmission.